Floatz logo

Regorafenib

BRAF V600E Negative

Academic and Community Cancer Research UnitedSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the BRAF V600E Negative cohort.

Asset / SponsorPhaseRating
Cetuximab
Academic and Community Cancer Research United
Phase 2CCC
Irinotecan
Academic and Community Cancer Research United
Phase 2CCC
PANITUMUMAB
Academic and Community Cancer Research United
Phase 2CCC

Same molecule, other indications

Regorafenib is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
RegorafenibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →